Zenas BioPharma Inc.

Last updated September 27, 2026

Organization details

Legal name
Zenas BioPharma Inc.
Former names
Zenas BioPharma (Cayman) Ltd
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Waltham
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
ZBIO
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001953926

Board of directors

Chief executives

Leon O. Moulder Jr. · Chief Executive Officer
Dates unknown

Director election results

Annual meeting of May 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

8 of this board's directors also sit on 22 other boards.

Network of Zenas BioPharma Inc.'s board connections Dianthus Therapeutics Inc. Dianthus Therapeutics... Crescent Biopharma Inc. Crescent Biopharma Inc... Jade Biosciences Inc. Jade Biosciences Inc. Korsana Biosciences Inc. Korsana Biosciences In... Oruka Therapeutics Inc. Oruka Therapeutics Inc... Spyre Therapeutics Inc. Spyre Therapeutics Inc... Vera Therapeutics Inc. Vera Therapeutics Inc. Viridian Therapeutics Inc. Viridian Therapeutics... Addex Therapeutics Ltd Addex Therapeutics Ltd Arrowhead Pharmaceuticals Inc. Arrowhead Pharmaceutic... Bicara Therapeutics Inc. Bicara Therapeutics In... BioAge Labs Inc. BioAge Labs Inc. CAMP4 Therapeutics Corporation CAMP4 Therapeutics Cor... Cogent Biosciences Inc. Cogent Biosciences Inc... Compass Therapeutics Inc. Compass Therapeutics I... Damora Therapeutics Inc. Damora Therapeutics In... Christy J. Oliger Christy J. Oliger Hongbo Lu Hongbo Lu James P. Boylan James P. Boylan Jason Raleigh Nunn Jason Raleigh Nunn Leon O. Moulder Jr. Leon O. Moulder Jr. Patrick G. Enright Patrick G. Enright Peter Evan Harwin Peter Evan Harwin Tomas Kiselak Tomas Kiselak Zenas BioPharma Inc.
Shared director Other board Same sector +6 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$29,046,629
25 purchases by 8 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
May 18, 2026 Leon O. Moulder Jr. Director, Officer (Chief Executive Officer) Open-market purchase +60,000 $16.88 $1,012,800
Apr 29, 2026 Leon O. Moulder Jr. Director, Officer (Chief Executive Officer) Open-market purchase +35,000 $17.62 $616,700
Apr 28, 2026 Leon O. Moulder Jr. Director, Officer (Chief Executive Officer) Open-market purchase +25,000 $18.02 $450,500
Mar 31, 2026 Hongbo Lu Director Open-market purchase +75,000 $20.00 $1,500,000
Mar 31, 2026 Hongbo Lu Director Open-market purchase +3,768 $18.63 $70,198
Mar 31, 2026 Tomas Kiselak Director Open-market purchase +150,000 $20.00 $3,000,000
Mar 31, 2026 Leon O. Moulder Jr. Director, Officer (Chief Executive Officer) Open-market purchase +34,000 $19.31 $656,540
Mar 30, 2026 Leon O. Moulder Jr. Director, Officer (Chief Executive Officer) Open-market purchase +20,000 $18.23 $364,600
Feb 13, 2026 Patricia L. Allen Director Open-market purchase +4,160 $26.36 $109,658
Feb 12, 2026 Patricia L. Allen Director Open-market purchase +5,000 $23.77 $118,850
Feb 12, 2026 Patricia L. Allen Director Open-market purchase +5,700 $24.34 $138,738
Feb 12, 2026 Patricia L. Allen Director Open-market purchase +5,000 $26.50 $132,500
Feb 11, 2026 Hongbo Lu Director Open-market purchase +25,985 $22.50 $584,663
Feb 5, 2026 Farmer Joseph L Officer (See Remarks) Grant or award +974 $13.35 $13,003
Feb 5, 2026 Jennifer A. Fox Officer (See Remarks) Grant or award +1,592 $13.35 $21,253

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.